Artificial organ

Artificial Organs Global Market Report 2023: A Potential $17.7 Billion Opportunity by 2027 - Benefits of Artificial Organs Over Traditional Transplants Drive Market Expansion - ResearchAndMarkets.com

Retrieved on: 
Monday, November 13, 2023
Hospitals, Health, Surgery, Medical Supplies, Kidney disease, COPD, Artificial organ, Prevalence, Cardiomyopathy, Investment, Liver cancer, Pelvic floor dysfunction, End organ damage, Idiopathic pulmonary fibrosis, Pulmonary hypertension, Viral, Inflammation, Chronic obstructive pulmonary disease, Blood, Organ transplantation, Ageing, Infection, Myocarditis, Growth, Cystic fibrosis, Moyamoya disease, Organic, Accident, Sonova, LivaNova, Smoking, Blood pressure, Aquaculture, Dentistry

This report is a comprehensive study of the global artificial organs market.

Key Points: 
  • This report is a comprehensive study of the global artificial organs market.
  • It describes the artificial organs market, segmented by product type and region.
  • Based on product type, the market is segmented into artificial hearts, artificial kidneys, artificial lungs, artificial pancreases, and cochlear implants.
  • Emerge more prepared and stay at the forefront of the global artificial organs market.

Spectral Medical Announces Positive Results of EUPHAS-2 Clinical Trial Evaluating PMX in Critically Ill Endotoxemic Septic Shock Patients

Retrieved on: 
Tuesday, April 18, 2023
Observational study, SOFA, Perfusion, Infection, EA, Research, Septic shock, Sepsis, Patient, PMX, TSX, Artificial organ, EAA, Pharmaceutical industry, Birth control

TORONTO, April 18, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced positive results in EUPHAS-2, an observational study in Italy using EAA-guided PMX hemoadsorption as a treatment for patients with endotoxemic septic shock. The results were featured in Artificial Organs, a premier, peer-reviewed journal publishing the latest in research, development, translation, and clinical application of organ replacement therapies, and organ machine perfusion preservation.

Key Points: 
  • TORONTO, April 18, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced positive results in EUPHAS-2, an observational study in Italy using EAA-guided PMX hemoadsorption as a treatment for patients with endotoxemic septic shock.
  • The study analysis included 50 patients with septic shock and endotoxin activity (EAT0) ≥ 0.6, who received Polymyxin-B hemoadsorption (PMX) therapy.
  • Among patients in the study, septic shock was mainly caused by 27 abdominal (54%) and 17 pulmonary (34%) infections.
  • Furthermore, as seen in EUPHAS-2 in patients with decreasing EAA, recovery from septic shock was faster.

Asia Pacific Artificial Organs and Bionics Markets, Competition, Forecast & Opportunities, 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 27, 2023
Cardiology, Biotechnology, Managed Care, Other Health, Diabetes, Health, General Health, Health Technology, Medical Devices, Hospitals, Surgery, Forecast, Disability, Accident, Artificiality, Bionics, Pelvic floor dysfunction, Organic, Country, 3D bioprinting, Competition, Artificial organ, Artificial intelligence, Kidney, Amputation, Growth, Conditional sentence, Environment, Video game, Retail, Agriculture, Tissue paper, Others

Asia Pacific artificial organs and bionics market is expected to grow at a significant rate during the forecast period, 2024-2028.

Key Points: 
  • Asia Pacific artificial organs and bionics market is expected to grow at a significant rate during the forecast period, 2024-2028.
  • To analyze and forecast the market size of Asia Pacific artificial organs and bionics market.
  • To classify and forecast Asia Pacific artificial organs and bionics market based on product, technology, material, end-user, company and country.
  • Company Profiles: Detailed analysis of the major companies present in Asia Pacific artificial organs and bionics market.

Insights on the Artificial Organs and Medical Bionics Global Market to 2027 - Asia Pacific Advanced to Forefront of Global Market with Steady Rise in Surgical Procedures and Healthcare Expenditure - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 27, 2022
Biotechnology, Health, Surgery, Therapy, Degenerative disease, Incidence, Efficiency, Kidney failure, Organic, Religion, Artificial organ, Hearing loss, Bionics, Manifest and latent functions and dysfunctions, Patient, 3D bioprinting, Awareness, Metal, 2009 Davis Cup, CAGR, Pharmaceutical industry, Medical device

A steep reduction in organ donations has created a significant demand for artificial organs and medical bionics.

Key Points: 
  • A steep reduction in organ donations has created a significant demand for artificial organs and medical bionics.
  • Considering the robust demand, the global artificial organs and medical bionics market is projected to demonstrate remarkable growth prospects.
  • Such next-generation technological advancements are setting the stage for robust expansions in the global artificial organs and medical bionics market.
  • North America and Europe are expected to hold a major share in the global artificial organs and medical bionics market.

Azin Parhizgar To Chair Protembis’ New Board of Directors

Retrieved on: 
Thursday, September 15, 2022
Medical Devices, Finance, Hospitals, Venture Capital, Professional Services, Cardiology, Small Business, Biotechnology, Health, Capital, Safety, Doctor of Philosophy, Director, Brain, Steel Azin F.C., Biomechanical engineering, Brown University, IDE, Senior, U.S. Venture Partners, TAVR, Acquisition, COO, Femoral artery, Â, Patient, Johnson & Johnson, Physician, CEO, Technology, Artificial organ, Medtronic, Board of directors, Board, Emerging technologies, Boston Scientific, Aortic valve, Tissue engineering, AVE, Pharmaceutical industry, Bordeaux wine

Protembis GmbH , a privately-held emerging cardiovascular medical device company, announced today the appointment of highly experienced and successful serial entrepreneur and medical device executive Azin Parhizgar (Ph.D.) as an Independent Member and Chairwoman of the Board of Directors.

Key Points: 
  • Protembis GmbH , a privately-held emerging cardiovascular medical device company, announced today the appointment of highly experienced and successful serial entrepreneur and medical device executive Azin Parhizgar (Ph.D.) as an Independent Member and Chairwoman of the Board of Directors.
  • Prior to Claret Medical, Azin served as the COO of Conor Medsystems, which led to the acquisition of the company by Johnson & Johnson.
  • It is both exciting and an honor for us that Azin has chosen to lead our Board of Directors as new Chairwoman, said Karl von Mangoldt and Conrad Rasmus, Co-CEOs of Protembis.
  • I am convinced that there is a need for a simple and effective next generation complete cerebral protection system notes Azin Parhizgar.

CroíValve Raises an €8M Series A Round to Support a Feasibility Clinical Study

Retrieved on: 
Monday, February 7, 2022
Biotechnology, Medical Devices, Health, Clinical Trials, Cardiology, Board of directors, Trinity College, Brown University, Senior, HBAN, SOSV, Multimedia, Elkstone, Enterprise Ireland, Woman, Board, Medtronic, Leadership, Technology, Patient, Norwest Venture Partners, Blood, Biomechanical engineering, CEO, Quality, Medtech, Boston Scientific, Regulatory affairs, COO, Feasibility, Capital, Artificial organ, Johnson & Johnson, Tissue engineering, AVE, Bachelor of Science, Trinity College Dublin, Medical device, Pharmaceutical industry, Chemical industry, Cephea

CroValve, a Dublin based medical device company developing a novel treatment for tricuspid regurgitation, has raised a Series A round to fund a Feasibility clinical study with its DUO Coaptation Valve system.

Key Points: 
  • CroValve, a Dublin based medical device company developing a novel treatment for tricuspid regurgitation, has raised a Series A round to fund a Feasibility clinical study with its DUO Coaptation Valve system.
  • Additionally, CroValve welcomes Dr. Azin Parhizgar, Ph.D., a leading medical device entrepreneur in structural heart, to its Board of Directors.
  • In addition, Helen Scotch has joined the Senior Leadership Team as Vice President of Clinical and Regulatory Affairs.
  • The funding will support a European Feasibility Study of the CroValve Transcatheter Tricuspid DUO Coaptation Valve System.

Tissue and Organ Transplantation Market Research Report 2020 - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 2, 2021
Surgery, Health, Organ transplantation, Medical specialties, Organ, Surgery, Artificial organ, Clinical medicine, Medicine, Transplantation medicine

The "Tissue and Organ Transplantation Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tissue and Organ Transplantation Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • Organ transplantation is the surgical operation carried out for replacement of damaged organ of an individual.
  • Whereas in some cases, an artificial organ is used for the transplantation procedure.
  • The global tissue and organ transplantation market is expected to witness significant growth during the forecast period, owing to the technological advancements in transplantation procedures.

Worldwide Artificial Organ and Bionics Industry to 2025 - Advantageous in Comparison Prosthetics Presents Opportunities

Retrieved on: 
Tuesday, April 13, 2021
Life sciences, Prosthetics, Robotics, Technology, Ekso Bionics, Biotechnology, Biological engineering, Medical robotics, Bionics, Powered exoskeleton, Artificial organ, Edwards Lifesciences

This has been a major boost for the artificial organ bionics market, as the patients cannot afford to wait in queue since the stakes are very high.

Key Points: 
  • This has been a major boost for the artificial organ bionics market, as the patients cannot afford to wait in queue since the stakes are very high.
  • Bionics and artificial organs are able to cater to the needs of those in need of organ transplantations and replacements.
  • In February 2020, Ekso Bionics Holdings, Inc. collaborated with Kindred Healthcare, LLC to pilot EksoNR - a robotic exoskeleton, in their long-term acute care hospitals.\n2.
  • In April 2019, Edwards Lifesciences Corporation acquired CAS Medical Systems, Inc., a medical technology company dedicated to non-invasive brain and tissue oxygenation monitoring.\n3.

Wearable Artificial Organs, Inc. Granted Patent for the Wearable Artificial Kidney (WAK) 3.0

Retrieved on: 
Wednesday, March 3, 2021
Health, Medical devices, Diabetes, Other Science, Clinical trials, Research, Science, Membrane technology, Nephrology, Artificial kidney, Medical specialties, Medicine, Artificial organ, Dialysis, Wearable, Clinical medicine

Victor Gura, MD, Chairman and Chief Scientific Officer of Wearable Artificial Organs Inc., announced today that the US Patent Office has granted approval of patent No.

Key Points: 
  • Victor Gura, MD, Chairman and Chief Scientific Officer of Wearable Artificial Organs Inc., announced today that the US Patent Office has granted approval of patent No.
  • Current stationary dialysis machines hinder mobility and limit activities in patients with End Stage Kidney Disease.
  • A miniaturized, battery operated wearable artificial kidney (WAK) can improve patient autonomy and has the potential to improve quality of life and reduce mortality.
  • ABOUT WEARABLE ARTIFICIAL ORGANS INC. (WAO)
    The company is a privately held Delaware corporation founded in 2017 to develop Dr. Guras latest invention.

Artificial Organs Market Revenue to Cross USD 33.5 Bn by 2026: Global Market Insights, Inc.

Retrieved on: 
Thursday, November 5, 2020
Prosthetics, Medicine, Medical specialties, Clinical medicine, Artificial organ, Testicle, Artificial kidney, Organ, Artificial heart, Automated insulin delivery systems

SELBYVILLE, Del., Nov. 5, 2020 /PRNewswire/ -- According to the latest report "Artificial Organs Market by Organ Type (Artificial Kidney, Artificial Liver, Artificial Lungs, Artificial Pancreas, Artificial Heart), By Material Type (Silicon, Plastic, Steel), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2026", by Global Market Insights, Inc., the market valuation of artificial organs will cross $33.5 billion by 2026.

Key Points: 
  • SELBYVILLE, Del., Nov. 5, 2020 /PRNewswire/ -- According to the latest report "Artificial Organs Market by Organ Type (Artificial Kidney, Artificial Liver, Artificial Lungs, Artificial Pancreas, Artificial Heart), By Material Type (Silicon, Plastic, Steel), Regional Outlook, Price Trends, Competitive Market Share & Forecast 2026", by Global Market Insights, Inc., the market valuation of artificial organs will cross $33.5 billion by 2026.
  • Artificial organs offer an effective solution to minimize the death burden due to the unavailability of organs.
  • Along with the incidence of organ dysfunction, technological advancements in artificial organ devices are expected to fuel the artificial organs market expansion.
  • The artificial kidney segment dominated more than 50% of the artificial organs market share in 2019, led by significantly increasing kidney failures.